⚠️ Ibogaine has caused cardiac arrest and death due to QTc prolongation and fatal arrhythmias. These risks are dose-dependent and can occur even in individuals with no prior cardiac history. Never undergo ibogaine treatment without a full cardiac workup, including a 12-lead ECG, performed by a qualified clinician.

Ibogaine Cardiac Risks and QTc Prolongation

Ibogaine is a powerful psychoactive alkaloid derived from the root bark of the Tabernanthe iboga shrub. It has shown significant promise in treating opioid use disorder and other addictions, but it carries a well-documented and serious cardiac risk profile. The primary danger is QTc interval prolongation — an abnormality in the heart's electrical cycle that can trigger life-threatening arrhythmias, including Torsades de Pointes (TdP) and ventricular fibrillation.

A 2012 review published in Cardiovascular Toxicology (Koenig & Hilber) identified ibogaine as a potent hERG potassium channel blocker — the same mechanism responsible for QTc prolongation caused by many withdrawn pharmaceutical drugs. This is not a rare edge-case risk; it is a pharmacological property of ibogaine itself.

What Is QTc Prolongation?

The QT interval on an electrocardiogram (ECG) represents the time it takes for the heart's ventricles to electrically depolarize and repolarize — essentially one full pumping cycle. The "corrected" QTc accounts for heart rate variation. A normal QTc is generally:

  • Under 440 ms in men
  • Under 460 ms in women

A QTc above 500 ms is considered a critical threshold associated with significantly elevated risk of Torsades de Pointes (TdP), a polymorphic ventricular tachycardia that can degenerate into ventricular fibrillation and sudden cardiac death.

Ibogaine has been documented to prolong QTc by 50–150+ ms in clinical settings (Medhurst et al., 2020; Brown & Alper, 2018). This means a patient with a borderline QTc of 460 ms before treatment could reach 560–610 ms during peak ibogaine effect — well into the danger zone.

Documented Deaths Linked to Cardiac Events

The cardiac risk of ibogaine is not theoretical. Multiple fatality reviews have documented deaths attributable to cardiac arrhythmia:

  • A 2012 case series by Macdonald et al. in Addiction reviewed 19 ibogaine-related fatalities. Most occurred within 72 hours of ingestion; cardiac arrhythmia was identified as the primary or contributing cause in the majority of cases.
  • A 2021 review by Litjens & Brunt documented that many fatalities occurred in uncontrolled settings without cardiac monitoring, in individuals who had QTc-prolonging drug interactions or undiagnosed structural heart disease.
  • The Global Ibogaine Therapist Alliance (GITA) clinical guidelines note that virtually all documented ibogaine deaths involved at least one identifiable risk factor that would have been caught by proper pre-treatment screening.

This is critical: the deaths are not random. They are largely preventable with rigorous screening and monitoring protocols.

Absolute Cardiac Contraindications

The following conditions represent absolute contraindications to ibogaine administration under most established clinical protocols (GITA, 2018; Noller et al., 2018):

  • Baseline QTc ≥ 450 ms (some protocols use ≥ 440 ms as the cutoff)
  • Congenital long QT syndrome (LQTS) — any type
  • History of Torsades de Pointes or ventricular fibrillation
  • Structural heart disease — including hypertrophic cardiomyopathy, dilated cardiomyopathy, and significant valvular disease
  • Symptomatic bradycardia or heart block (second- or third-degree AV block)
  • Recent myocardial infarction (typically within 6 months)
  • Uncontrolled hypertension or severe hypertension (systolic > 180 mmHg)
  • Heart failure with reduced ejection fraction (EF < 40%)
  • Wolff-Parkinson-White (WPW) syndrome or other accessory pathway syndromes

QTc-Prolonging Drug Interactions

Combining ibogaine with other QTc-prolonging substances is one of the most common factors in documented fatalities. The effect is additive or synergistic — each drug adds to the QTc interval independently. Critically, many opioids themselves prolong QTc, meaning patients seeking opioid detoxification arrive with an already-elevated baseline.

Known QTc-prolonging substances that represent serious interaction risks include:

  • Methadone — one of the most potent QTc-prolonging opioids; a required washout period of at least 5–7 days minimum is standard in most protocols, with many requiring longer. Methadone's long half-life (24–36 hours) complicates this significantly.
  • Antipsychotics — haloperidol, quetiapine, risperidone, olanzapine, ziprasidone
  • Antidepressants — citalopram, escitalopram, tricyclic antidepressants (amitriptyline, imipramine)
  • Antibiotics — azithromycin, clarithromycin, ciprofloxacin, moxifloxacin
  • Antifungals — fluconazole, ketoconazole
  • Antiarrhythmics — amiodarone, sotalol, quinidine
  • Antiemetics — ondansetron (Zofran), domperidone
  • Stimulants — cocaine, amphetamines (also cause hypertension and additional cardiac stress)
  • Other psychedelics — particularly other serotonergic compounds that may interact unpredictably

The full CredibleMeds/AZCERT database (crediblemeds.org) lists hundreds of QTc-prolonging drugs. Any patient taking any medication must have a comprehensive medication review against this database before ibogaine is considered.

Electrolyte Imbalances as an Additional Risk Factor

Electrolyte abnormalities independently prolong QTc and dramatically compound ibogaine's cardiac risk. Patients undergoing opioid or alcohol withdrawal are at particularly high risk because vomiting, diarrhea, poor nutrition, and sweating deplete critical electrolytes.

Electrolytes that must be within normal range before treatment:

  • Potassium (K⁺) — hypokalemia is one of the most potent QTc-prolonging conditions. Target: 3.5–5.0 mEq/L
  • Magnesium (Mg²⁺) — hypomagnesemia extends QTc and impairs potassium repletion. Target: 1.7–2.2 mg/dL
  • Calcium (Ca²⁺) — hypocalcemia prolongs the QT interval directly

Reputable protocols require electrolyte panels within 24–48 hours of ibogaine administration and correction of any deficiencies before proceeding.

Required Pre-Treatment Cardiac Screening

The minimum cardiac screening required by established clinical protocols (GITA, 2018; Multidisciplinary Association for Psychedelic Studies clinical guidance) includes:

  1. 12-lead ECG — interpreted by a cardiologist or trained physician. Must confirm QTc within acceptable range (typically < 440–450 ms). Performed within 30 days of treatment, ideally within 1 week.
  2. Complete metabolic panel (CMP) — includes electrolytes, kidney function (creatinine, BUN), and liver enzymes
  3. Complete blood count (CBC)
  4. Comprehensive medication history — including all prescription, OTC, herbal, and recreational substances
  5. Cardiac history review — personal and family history of sudden cardiac death, arrhythmias, syncope, or congenital heart conditions
  6. Echocardiogram — required if there is any history of structural heart disease, murmur, reduced exercise tolerance, or unexplained symptoms
  7. Holter monitor (24–48 hour ambulatory ECG) — recommended when there is any history of palpitations, syncope, or abnormal baseline ECG findings

Do not accept treatment from any provider who does not require a recent 12-lead ECG with physician review as a minimum. This is non-negotiable.

Monitoring During Ibogaine Administration

Cardiac risk does not end with pre-treatment screening. The acute ibogaine experience — typically lasting 18–36 hours — requires continuous or near-continuous monitoring because QTc prolongation peaks during the treatment window itself.

Established protocols require:

  • Continuous cardiac monitoring via telemetry or pulse oximetry + ECG throughout the acute phase
  • Repeated 12-lead ECGs at baseline, at peak effect (approximately 1–3 hours post-dose), and every 4–6 hours during the acute phase
  • Immediate access to emergency resuscitation equipment: defibrillator (AED or manual defibrillator), IV access, oxygen, and medications to treat arrhythmia (e.g., magnesium sulfate IV for TdP)
  • On-site or immediately available medical personnel trained in advanced cardiac life support (ACLS)
  • Vital signs monitoring — blood pressure, heart rate, oxygen saturation every 30–60 minutes during the acute phase

The post-acute phase (24–72 hours after dosing) also carries risk as ibogaine and its active metabolite noribogaine are metabolized and cleared. Monitoring should continue with clinical assessment and repeat ECG before the patient is discharged.

Noribogaine: The Active Metabolite That Prolongs Risk

Ibogaine is rapidly metabolized in the liver to noribogaine, which is itself pharmacologically active and also prolongs QTc. Noribogaine has a significantly longer half-life than ibogaine (estimated 28–49 hours in some studies vs. ibogaine's 4–7 hours), meaning cardiac risk is not limited to the acute psychedelic phase but extends well into the recovery period (Glue et al., 2015).

This is why patients must not be discharged immediately after the psychedelic experience ends, and why QTc-prolonging medications must be withheld for an extended period after treatment — not just before.

Red Flags: Questions to Ask Any Provider

When evaluating a treatment provider, the following practices are non-negotiable safety indicators. Walk away from any provider who cannot affirmatively answer all of these:

  • Do you require a 12-lead ECG reviewed by a physician within the past 30 days?
  • Do you require a full blood panel including electrolytes?
  • Do you have continuous cardiac monitoring (telemetry) available during the session?
  • Is there a physician or ACLS-certified provider on-site throughout the entire acute phase?
  • Do you have a defibrillator and emergency medications (including IV magnesium) on the premises?
  • Do you perform a full medication review against a QT-prolonging drug database?
  • What is your protocol if a patient's QTc exceeds your threshold during treatment?

Frequently Asked Questions

Most established clinical protocols set the upper safe limit at 440–450 ms on a pre-treatment 12-lead ECG. Some conservative protocols use 430 ms for women. A QTc at or above 450 ms is generally considered an absolute contraindication. Even within the "acceptable" range, providers should interpret the ECG in the context of the patient's full history — borderline values in a patient with other risk factors (e.g., electrolyte imbalances, QTc-prolonging medications) may still make ibogaine inadvisable. The 12-lead ECG must be read by a qualified physician, not simply printed and handed to the patient.
Methadone is one of the most significant risk factors for ibogaine-related cardiac death. Methadone itself is a potent QTc-prolonging agent, and it has an extremely long and variable half-life (24–36+ hours), meaning it remains in the body long after the last dose. The combination of methadone and ibogaine has been involved in multiple documented fatalities. Reputable protocols require a transition off methadone — typically to a shorter-acting opioid — well in advance of treatment, with a washout period of at least 5–7 days, and often longer depending on the dose and individual metabolism. This transition must be medically supervised. Do not attempt to self-discontinue methadone; doing so carries its own serious risks including precipitated withdrawal and relapse.
Not every instance of QTc prolongation leads to a dangerous arrhythmia, but the risk increases substantially as QTc rises above 500 ms. Ibogaine reliably prolongs QTc — this is a pharmacological certainty, not a possibility. The degree of prolongation varies by dose, individual metabolism (CYP2D6 enzyme activity plays a significant role), and the presence of additional risk factors. In a controlled clinical setting with proper screening, continuous monitoring, and emergency equipment available, ibogaine can be administered with substantially reduced (though not eliminated) cardiac risk. In uncontrolled settings without monitoring, the same degree of QTc prolongation can be fatal because there is no capacity to detect and respond to arrhythmia. This is why setting and provider qualifications matter profoundly.
Torsades de Pointes (TdP), the most likely serious arrhythmia from QTc prolongation, can be treated with intravenous magnesium sulfate (2 g IV over 1–2 minutes), which is why IV magnesium is a required emergency medication in all reputable ibogaine protocols. If TdP degenerates into ventricular fibrillation, immediate defibrillation is required — which is why a defibrillator must be physically present during treatment. Sustained TdP or VF requires Advanced Cardiac Life Support (ACLS) protocols and emergency transfer to a hospital. Fatalities occur when these interventions are unavailable — when there is no monitoring to detect the arrhythmia, no defibrillator, no IV access, and no trained personnel. This is why underground or inadequately equipped settings carry disproportionate risk.
Yes — QTc prolongation from ibogaine is dose-dependent, meaning higher doses produce greater QTc prolongation. "Flood" doses (typically 15–25 mg/kg or higher, used for full psychedelic and addiction-interruption effect) carry significantly more cardiac risk than lower "test" or "microdose" ranges. However, even lower doses can cause clinically meaningful QTc prolongation, and no dose is without cardiac risk, particularly in susceptible individuals. Some protocols use a test dose (typically 1–3 mg/kg) administered with full cardiac monitoring before proceeding to a full dose — this allows clinicians to observe the individual's cardiac response before committing to the full treatment dose. Even this approach requires all the same screening and monitoring infrastructure.
Due to noribogaine (ibogaine's active metabolite), QTc prolongation can persist for 48–72 hours or more after the psychedelic effects subside. Research by Glue et al. (2015) found noribogaine plasma concentrations remained detectable and pharmacologically relevant for up to 48+ hours post-dosing. Reputable protocols therefore continue cardiac monitoring — including serial ECGs — throughout this post-acute window and do not restart QTc-prolonging medications until the QTc has returned to baseline and sufficient time has passed for noribogaine clearance. Patients should also avoid strenuous exertion, stimulants, and any new QTc-prolonging substances for at least 48–72 hours post-treatment.

Sources

  • Koenig X, Hilber K. "The anti-addiction drug ibogaine and the heart: a delicate relation." Molecules. 2015;20(2):2208–2228. doi:10.3390/molecules20022208
  • Macdonald AJ, et al. "Ibogaine-related deaths." Addiction. 2012. (Case series review of 19 fatalities)
  • Brown TK, Alper K. "Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes." American Journal of Drug and Alcohol Abuse. 2018;44(1):24–36.
  • Glue P, et al. "Ascending-dose study of noribogaine in healthy volunteers." Journal of Clinical Pharmacology. 2015;55(2):189–194.
  • Noller GE, Frampton CM, Yazar-Klosinski B. "Ibogaine treatment outcomes for opioid dependence." American Journal of Drug and Alcohol Abuse. 2018;44(1):47–55.
  • Global Ibogaine Therapist Alliance (GITA). Clinical Guidelines for Ibogaine-Assisted Detoxification. 2018. gita.training
  • Litjens RPW, Brunt TM. "How toxic is ibogaine?" Clinical Toxicology. 2016;54(4):297–302.
  • Medhurst SJ, et al. Ibogaine pharmacology and cardiac effects. Referenced in multiple clinical protocol reviews, 2020.
  • CredibleMeds/AZCERT QTDrugs List. crediblemeds.org. (QTc-prolonging drug database)

Informational only. Not medical advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.